Hughes G G - OmicsDI

Show results for

Unknown (7041)
Proteomics (275)
Transcriptomics (111)
Genomics (34)
Metabolomics (11)
Models (2)
Genomic (2)

Organisms

Allexis (272)
Arabidopsis thaliana (272)
Callinectes sapidus (272)
Drosophila (272)
Drosophila melanogaster (272)
Mus musculus (41)
Homo sapiens (40)
Saccharomyces cerevisiae (17)
synthetic construct (12)
Apis mellifera (4)
Rattus norvegicus (3)
Arabidopsis thaliana (3)
Glycine max (2)
Drosophila melanogaster (2)
Plasmodium berghei (2)
Escherichia coli K-12 (1)
cellular organisms (1)
Lactobacillus helveticus (1)
Acropora palmata (1)
Gossypium barbadense (1)
Populus x canadensis (1)
Tetraodon nigroviridis (1)
Fusobacterium nucleatum (1)
Macaca mulatta (1)
Oryza sativa (1)
Mycobacterium tuberculosis (1)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
Canis lupus familiaris (1)
Escherichia coli (1)
Gallus gallus (1)

Organisms

Populus x canadensis (1)
Severe acute respiratory syndrome coronavirus 2 (1)
Plasmodium berghei (1)

Repository

pride (272)
biostudies-arrayexpress (134)
MetaboLights (10)
EGA (7)
ENA (4)
MassIVE (3)
BioModels (2)
dbGaP (2)
geo (1)
GNPS (1)

Tissue

Cell culture (59)
Brain (30)
Permanent cell line cell (14)
Epithelial cell (13)
Liver (13)
Embryonic stem cell (7)
B cell (6)
Lung (6)
Blood (5)
Colon (5)
Endothelial cell (5)
Microglial cell (5)
T cell (5)
Blood plasma (4)
Blood serum (4)
Fibroblast (4)
Heart (4)
Neutrophil (4)
Hepatocyte (3)
Leaf (3)
Macrophage (3)
Seed (3)
Whole body (3)
B-cell chronic lymphocytic leukemia cell (2)
Blood cell (2)
Bone marrow (2)
Breast cancer cell (2)
Bronchial epithelial cell (2)
Embryo (2)
HeLa cell (2)

Disease

Breast cancer (6)
Disease free (5)
Acute leukemia (4)
Alzheimer's disease (4)
Chronic lymphocytic leukemia (4)
Lung cancer (4)
COVID-19 (3)
Niemann-Pick disease (3)
Normal (2)
Brain cancer (2)
Colitis (2)
Malignant neoplasm of ovary (2)
Neuroblastoma (2)
Niemann-Pick disease type C1 (2)
Parkinson's disease (2)
Prostate adenocarcinoma (2)
Hepatomegaly (1)
Atherosclerosis (1)
Bone osteosarcoma (1)
Brain glioblastoma multiforme (1)
Cardiovascular system disease (1)
Cerebral amyloid angiopathy (1)
Cervix carcinoma (1)
Chronic neutrophilic leukemia (1)
Colon cancer (1)
Diffuse midline glioma (1)
Focal segmental glomerulosclerosis (1)
Glioblastoma (1)
Heart failure (1)
Hepatocellular carcinoma (1)

Technology Type

Mass Spectrometry (272)
Shotgun proteomics (137)
Bottom-up proteomics (72)
Affinity purification coupled with mass spectrometry proteomics (34)
Data-independent acquisition (34)
Data-dependent acquisition (33)
SWATH MS (14)
Gel-based experiment (10)
Top-down proteomics (9)
Mass spectrometry (6)
All-ion fragmentation (4)
Chemical cross-linking coupled with mass spectrometry proteomics (4)
HDMSE (4)
NMR spectroscopy (3)
DiaPASEF (2)
Illumina HiSeq 2000 (1)
Mass spectrometry assay (1)
Affinity proteomics (1)
SRM/MRM (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (6)
Liquid Chromatography MS - negative - reverse phase (5)
NextSeq 500 (4)
Q Exactive (2)
SYNAPT G2-Si (2)
TSQ Altis (2)
Xevo G2 XS Tof (2)
Xevo G2-XS QTof (2)
Bruker (2)
Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - positive - hilic (2)
BD FACS Aria II (1)
HiSeq X Five (1)
Illumina MiSeq (1)
Illumina HiSeq 1500 (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 4000 (1)
Orbitrap Exploris 480 (1)
Orbitrap Fusion Lumos (1)
Xevo TQ MS (Waters) (1)
Direct infusion MS - negative (1)
Nuclear Magnetic Resonance (NMR) (1)
Direct infusion MS - positive (1)
Liquid Chromatography MS - (1)

Publication Date

2026 (55)
2025 (49)
2024 (42)
2022 (42)
2023 (37)
2010 (27)
2013 (26)
2020 (25)
2021 (22)
2015 (13)
2009 (13)
2012 (10)
2011 (10)
2008 (9)
2019 (9)
2016 (8)
2018 (7)
2017 (5)
2014 (5)
2007 (3)
2006 (2)
2004 (2)
2005 (1)
2003 (1)

UNIPROT ID/AC

P07659 (1)
P00573 (1)
P42212 (1)

CHEBI ID

CHEBI:28300 (5)
CHEBI:25017 (5)
CHEBI:26271 (4)
CHEBI:17126 (4)
CHEBI:18186 (4)
CHEBI:28044 (4)
CHEBI:29016 (4)
CHEBI:16919 (4)
CHEBI:25094 (3)
CHEBI:18237 (3)
CHEBI:22660 (3)
CHEBI:22653 (3)
CHEBI:26986 (3)
CHEBI:16811 (3)
CHEBI:17234 (3)
CHEBI:24898 (3)
CHEBI:15428 (3)
CHEBI:27266 (3)
CHEBI:17750 (3)
CHEBI:16449 (3)
CHEBI:78320 (3)
CHEBI:16737 (3)
CHEBI:17368 (3)
CHEBI:33699 (2)
CHEBI:15361 (2)
CHEBI:17768 (2)
CHEBI:17172 (2)
CHEBI:33697 (1)
CHEBI:17535 (1)
CHEBI:36080 (1)

Metabolite Name

Glutamate (4)
Leucine (4)
Aspartate (4)
Lactate (4)
Glycine (3)
Valine (3)
Tyrosine (3)
Alanine (3)
Threonine (3)
Proline (3)
Phenylalanine (3)
Isoleucine (3)
Glutamine (3)
Creatinine (3)
Creatine (3)
Hypoxanthine (3)
Acetate (2)
Malate (2)
Histidine (2)
Acetoacetate (2)
Betaine (2)
Citrulline (2)
Pantothenate (2)
Ornithine (2)
Carnitine (2)
Methionine (2)
Choline (2)
Taurine (2)
Arginine (2)
Lysine (2)

First Public Date

2014 (2)
2022 (1)
2021 (1)

Modelling Approach

Ordinary differential equation model (2)

Lab affiliation

DZNE Munich, Neuroproteomics, Feodor-Lynen Str. 17, 81377 Munich, Germany (8)
David H. Koch Institute for Integrative Cancer Research Howard Hughes Medical Institute Massachusetts Institute of Technology Cambridge, MA 02139, USA (6)
DZNE Munich, Neuroproteomics, Feodor-Lynen-Str. 17, 81377 München, Germany (4)
Proteomics facility, Central Science Laboratory, University of Tasmania (4)
University of Dundee, School of Life Sciences (4)
Analytics Core Facility Essen (ACE), Chemische Biologie, Universität Duisburg-Essen, ZMB, Germany (3)
Division of Proteomics of Stem Cells and Cancer (3)
Klinik II für Innere Medizin: Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin Zentrum für Molekulare Medizin Köln (ZMMK) Uniklinik Köln Kerpener Str. 62 D-50937 Köln (3)
Max Perutz Labs, Vienna, Austria (3)
Max-Planck-Institute for Biology of Ageing Department of Mitochondrial Proteostasis Joseph-Stelzmann-Str. 9b 50931 Cologne (3)
Cambridge Institute for Medical Research, University of Cambridge (2)
Department of Oncology-Pathology, Karolinska Institute and Scilifelab, Solna, Sweden (2)
Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany (2)
Division of Surgery, Oncology, and Pathology, Department of Clinical Sciences. Biomedical Center – Lund University, Solvegatan 19, 223 62, Lund, Sweden (2)
Forschungszentrum Jülich (2)
Harvard Medical School Cell Biology Department (2)
Harvard Medical School, Department of Cell Biology Howard Hughes Medical Institute (2)
Howard Hughes Medical Institute NYU School of Medicine-Smilow Research Center Biochemistry Department (2)
The University of Sydney, School of Life and Environmental Sciences, Charles Perkins Centre, Sydney, New South Wales, Australia. (2)
Univ. Bordeaux, INSERM, CRCTB, U 1045, F-33000 Bordeaux, France (2)
Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Biology, Cambridge, MA, USA (2)
Woods Hole Oceanographic Institution, Marine Chemistry and Geochemistry Department (2)
1) Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany 2) CECAD, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (1)
1. Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, AUSTRALIA 2. Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, AUSTRALIA 3. Paediatric Program, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing, Callaghan, NSW, AUSTRALIA (1)
1. Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 115 27 Athens, Greece. 2. Joint Rheumatology Program, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, 124 62 Athens, Greece. (1)
1.Department of Molecular Biology and Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, MA 02114, USA, 2.Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA, 3.Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. (1)
1.Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA 2.Department of Microbiology, Harvard Medical School, Boston, MA, USA 3.Howard Hughes Medical Institute, Boston, MA, USA (1)
1Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital – Bispebjerg and Frederiksberg; Copenhagen, Denmark 2Department of Clinical Medicine, University of Copenhagen; Denmark (1)
4Cellular Proteome Research, Helmholtz Centre for Infection Research, Braunschweig, Germany (1)
Amphista Therapeutics Cambridge United Kingdom (1)

IsPrivate

False (2)

Classification

viruses (1)
protozoa (1)

Modification

Not available (1)

Study type

Transcription profiling by array (59)
ChIP-seq (22)
Other (20)
RNA-seq of coding RNA (10)
ChIP-chip by tiling array (6)
Unknown experiment type (5)
Transcription profiling by tiling array (3)
Comparative genomic hybridization by array (2)
High-throughput sequencing (1)
Capture-C (1)
DNA-seq (1)
Methylation profiling by array (1)
RNA-seq of coding RNA from single cells (1)
RNA-seq of non coding RNA (1)

Release Date

2022 (599)
2021 (550)
2020 (539)
2023 (502)
2018 (440)
2019 (429)
2014 (407)
2024 (398)
2015 (397)
2016 (390)
2025 (383)
2017 (351)
2013 (278)
2012 (259)
2011 (246)
2010 (218)
2009 (193)
2008 (148)
2007 (73)
2006 (73)
2005 (56)
2026 (48)
2004 (36)
2003 (33)
2002 (29)
2001 (24)
1999 (22)
1998 (22)
2000 (17)
1997 (11)

Previous page
1 / 748
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 748
Next page

Sort by:

Relevance

Page size

A SNF2 protein targets variable copy number repeats and thereby influences allele-specific expression

ATRX is an X-linked gene of the SWI/SNF family whose role in vivo is currently unknown. Mutations in ATRX cause syndromal mental retardation. ATRX binds to tandem repeat (TR) sequences both in heterochromatin (e.g. telomeres) and euchromatin. Genes associated with these TRs can be dysregulated when ...

ORGANISM(S): Homo sapiens

2010-11-02 | E-GEOD-22162 | biostudies-arrayexpress

G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients

Despite advancements in cancer therapies, bacterial complications remain a major challenge, delaying treatment and worsening outcomes. While immunosuppressive therapies and prolonged hospitalizations contribute, they do not fully explain the elevated infection risk in cancer patients. Here we show t...

ORGANISM(S): Mus musculus (Mouse)

2025-10-17 | PXD069569 | Pride